

HEDGEHOG, Inc.

Category	Enterprise Creation
<input type="radio"/> Corporation (Preliminary Enterprise)	HEDGEHOG, Inc.
<input type="radio"/> Representative	Sang Cheul Oh
<input type="radio"/> Establishment year	Nov 2018
<input type="radio"/> Specialized Field	Development of Antibody/Synthetic/Natural Anti-cancer Drugs
<input type="radio"/> Address	#204, 2F, 226, Gamasan-ro, Guro-gu, Seoul, Republic of Korea
<input type="radio"/> Home page	- Homepage: www.hedgehogtec.com
<input type="radio"/> Enterprise Brief Introduction	We are developing a new anticancer drug that targets Hedgehog, a gene that is overexpressed in various cancers and is involved in embryonic development and cell growth.
<input type="radio"/> Product and Pipeline Introduction	<ol style="list-style-type: none"> 1. HH101: Mouse-derived fully humanized SMO antibody. 2. HH102: Anti-Human EPHB3 Single Clone Antibody. EPHB3 single-clone human antibodies are being developed as first in class antibody treatments that competitively inhibit the binding of EPHB3 and the ligand Eprin. 3. HH103: Anti-Human ETAR Single Clone Antibody. We are developing a new anti-cancer drug that competitively inhibits the combination of ETAR and ligand Endothelin. 4. HH201: It is a low-molecular compound treatment that inhibits the role of GLI transcription factors and is being developed as a best in class treatment that has a differential effect from the existing treatment.
<input type="radio"/> Patent and Certification, Licensing, Thesis, Investment status, etc.	(Patent) 2 applications in Korea 3 registrations in Korea 3 applications in Overseas (Certification) Venture company confirmation_2020.12.28. (Licensing) Establishment of research institute.